Enzalutamide approved in EU for metastatic hormone-sensitive prostate cancer
The approval was based on data from the 3 ARCHES trial.
Related Articles
Dr. Matin discusses early work with FGFR inhibition in localized UTUC
“And [3 out of 5] of those patients who were initially deemed to go on to nephroureterectomy were able to be converted to endoscopic management,”…
FDA approves pivmecillinam tablets for uncomplicated UTIs
The approval is based on 3 clinical trials evaluating the efficacy of different pivmecillinam dosing regimens in comparison with either placebo, another oral antibacterial drug,…
AUA 2024: Dr. Weiner previews key prostate cancer research
Adam B. Weiner, MD, highlights several studies in prostate cancer set to be presented at the upcoming 2024 American Urological Association Annual Meeting.
Use of PDE-5 inhibitors and beta-3 agonists in treating BPH
“Within this paper, we discussed the importance of conservative management and lifestyle modifications as initial steps in managing BPH,” says Eiftu S. Haile, MD.
Cystoscope Preferences and Practices in Urology
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Enzalutamide granted approval in EU for nmHSPC
The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with…
Studies launch of copper Cu 64 PSMA I&T PET/CT in prostate cancer
Both the SOLAR-STAGE and SOLAR-RECUR trials are currently enrolling patients with prostate cancer in the US, with additional sites expected to open in Europe later…
Dr. Marhamati on initial outcomes with Aquablation in ASC setting
In this final iteration of a 3-part series, Shawn H. Marhamati, MD, MS, shares initial insights into benefits of Aquablation in an ASC environment.
2024 AUA preview: Dr. Tawagi on top research in bladder cancer
Karine Tawagi, MD, highlights several studies in bladder cancer being presented at the 2024 American Urological Association Annual Meeting.
Published OASIS trial data show safety, efficacy of Revi system for OAB
Findings from the study showed a clinical response rate of 76.4% and 78.4% at 6- and 12-months following activation of the device among patients in…